What Are the Phases of a Clinical Trial

By Kevin Fernando · Sep 8, 2026 · 9 min read

Clinical trials proceed through four sequential phases: Phase 1 tests safety and dosage in 20-100 participants, Phase 2 measures effectiveness in 100-300 patient volunteers, Phase 3 confirms efficacy in 300-3,000+ patients across multiple sites, and Phase 4 monitors safety after FDA approval. Pre-clinical testing and regulatory review occur before Phase 1 begins.

Clinical trials proceed through four sequential phases: Phase 1 tests safety and dosage in 20-100 participants, Phase 2 measures effectiveness in 100-300 patient volunteers, Phase 3 confirms efficacy in 300-3,000+ patients across multiple sites, and Phase 4 monitors safety after FDA approval. Pre-clinical testing and regulatory review occur before Phase 1 begins.

Clinical trials are not a single test. They are a standardized regulatory sequence in which a drug candidate passes through four distinct phases, each measuring something different and each designed to answer a specific question about safety or effectiveness. Understanding what each phase tests, how many people participate, and what data it produces is essential for investors and analysts evaluating pharmaceutical companies and their development pipelines.

The structure exists because rushing to market without this evidence is dangerous, and because regulators need proof of both safety and efficacy before approving a drug for public use. A drug that works in a test tube may fail in animals. A drug that works in animals may harm humans. A drug that helps a small, carefully selected group may not work in the general population. Each phase builds on the last, progressively de-risking the candidate and narrowing the field of viable drugs. Most drug candidates fail somewhere in this sequence. Understanding where and why matters to assessing a company's pipeline and the probability that a particular drug will ever reach patients.

What clinical trial phases are

Clinical trials are structured experiments conducted on human volunteers to test whether a drug is safe and effective. The FDA divides this testing into four phases, each with a defined purpose, participant population, and success criteria. These phases are sequential, a drug must succeed in one phase before advancing to the next, and together they produce the evidence the FDA needs to decide whether to approve the drug for public use.

The phase structure exists because different questions require different experimental designs and different sample sizes. Testing whether a drug is toxic requires a small group of participants and careful monitoring of side effects. Testing whether a drug actually works requires a larger group of patients with the disease being treated. Testing whether a drug works better than existing treatments requires an even larger group and a comparison arm. Testing whether unexpected side effects emerge after millions of people use the drug requires post-market surveillance. Each phase answers one question well; no single trial could answer all of them.

Pre-clinical testing and IND application

Before any human is exposed to a drug candidate, the company must conduct pre-clinical development, laboratory and animal studies that establish whether the drug is safe enough to test in humans. This stage includes pharmacology studies (what the drug does to the body), toxicology studies (what harm it might cause), and pharmacokinetic studies (how the body processes it). These pre-clinical studies are collectively called IND-enabling studies.

The pre-clinical stage takes an average of 31.2 months from compound synthesis to the point where human testing can begin. Once this data is compiled, the company files an Investigational New Drug (IND) application with the FDA, which reviews the pre-clinical evidence and decides whether the risk to human participants is acceptable. If the FDA approves the IND application, the company may proceed to Phase 1.

Phase 1: Testing safety and dosage in small groups

Phase 1 is the first time a drug candidate is tested in humans. It enrolls a small group of 20-100 participants, typically healthy volunteers, though for serious diseases like cancer, participants may have the disease being studied. The primary goal is not to determine whether the drug works; it is to establish whether it is safe and to identify the maximum tolerated dose.

Phase 1 uses a dose-escalation design: researchers start with a low dose on a small cohort of participants, monitor them carefully for side effects, and if the drug is tolerated, give a higher dose to the next cohort. This process continues until researchers identify the maximum tolerated dose (MTD), the highest dose that does not cause unacceptable side effects, or a recommended Phase 2 dose (RP2D). Phase 1 trials last several months, with an average duration of 27.8 months across all therapeutic areas.

Phase 1 is a pass-or-fail gate. Approximately 70% of drugs that enter Phase 1 advance to Phase 2. The remaining 30% fail because they are too toxic, too unstable, or produce side effects that make further testing unethical.

Phase 2: Measuring efficacy and documenting side effects

Phase 2 shifts focus from safety to efficacy. It enrolls 100-300 volunteers, all of whom have the disease or condition being studied, not healthy volunteers. The trial typically lasts several months to two years, with an average duration of 34.0 months.

Phase 2 answers the question: Does this drug actually work? Researchers measure whether the drug produces the desired clinical effect, whether it shrinks tumors, lowers blood pressure, reduces symptoms, or achieves whatever outcome defines success for that disease. Phase 2 also continues to monitor side effects and documents the full range of adverse events at different doses.

At the end of Phase 2, a go-or-no-go decision is made. The company evaluates safety, tolerability, the optimal dose range, and early signs of activity to establish proof of concept. A key factor in this decision is the expected efficacy and the predicted probability of success in Phase 3. If the data is promising, the company proceeds to Phase 3. If the drug shows insufficient efficacy or unacceptable toxicity, development stops.

Phase 3: Confirming effectiveness and monitoring adverse events

Phase 3 is the largest and most expensive phase. It enrolls 300-3,000 or more patients across multiple clinical centers and typically lasts 2-5 years, with an average duration of 38.0 months.

Phase 3 is a randomized controlled trial, participants are randomly assigned to receive either the experimental drug or a control treatment. The control arm receives either the current standard of care (the best existing treatment) or a placebo, depending on the disease. The trial measures whether the experimental drug is more effective than the control.

Phase 3 trials are designed around primary endpoints, the specific clinical outcomes that directly measure benefit, and secondary and exploratory endpoints that provide additional information about efficacy or safety. These endpoints are defined before the trial begins. Success means the drug meets its primary endpoint with statistical significance and acceptable safety.

Phase 3 is where most drug development cost and time accumulate. It is also where most drugs fail. Approximately 65% of drugs that enter Phase 3 receive regulatory approval, meaning about one-third of candidates fail at this stage despite having shown promise in Phase 2.

Phase 4: Post-market surveillance after approval

Phase 4 begins after the FDA approves the drug and it enters the market. It is ongoing safety monitoring of the drug in the general population, people with different ages, comorbidities, medications, and disease severities than those enrolled in controlled trials.

Phase 4 includes postmarketing requirements (PMRs), studies the FDA mandates as a condition of approval, and postmarketing commitments (PMCs), studies the company has voluntarily agreed to conduct. The FDA has authority under the 2007 Food and Drug Administration Amendments Act to require drug manufacturers to conduct postmarket safety studies and clinical trials to assess possible serious risks. Phase 4 averages 36.6 months but often continues for years or indefinitely as the company monitors for rare side effects or new uses.

Phase 4 can reveal problems that earlier phases missed. If serious adverse events emerge, the FDA can restrict the drug's use, require additional warnings, or withdraw approval.

Why trial phases matter to drug development timelines and investor analysis

The phase structure directly shapes company risk and capital requirements. From laboratory discovery to FDA approval, a drug takes an average of 10-15 years, with clinical trials accounting for 6-8 of those years. Within that timeline, each phase represents a major capital commitment and a significant probability of failure.

A company with a drug in Phase 1 has years of testing ahead and faces the highest probability of eventual failure. A company with a drug in Phase 3 has invested substantially more capital and time, but faces a lower probability of failure than Phase 1. A company with an approved drug (Phase 4) has cleared the regulatory hurdle, but still faces post-market risks.

For investors and analysts, phase progression is a key measure of pipeline value and company risk. A drug advancing from Phase 2 to Phase 3 represents validation that the drug works, but also signals that the company will need capital to fund the expensive Phase 3 trial. A Phase 3 failure can eliminate years of investment and damage the company's credibility. A Phase 3 success moves the drug toward approval and potential revenue, but does not guarantee it, FDA review and manufacturing scale-up still lie ahead.

How to interpret phase data in company filings and research reports

When a company reports trial results in an earnings call, press release, or SEC filing, the announcement typically includes the phase, the endpoint that was measured, whether that endpoint was met, and any safety signals. Learning to read this data accurately is essential for assessing a drug candidate's viability.

A Phase 1 announcement usually states the maximum tolerated dose and whether the drug was well-tolerated. Success means the drug can be given to humans without unacceptable toxicity. A Phase 2 announcement states whether the drug met its primary efficacy endpoint and describes the side effect profile. Success means the drug works in the target population. A Phase 3 announcement states whether the drug met its primary endpoint versus control and whether the safety profile is acceptable. Success means the drug is more effective than current treatment (or placebo) and safe enough to approve.

Key details to look for: Was the primary endpoint met, or only secondary endpoints? Secondary endpoint success does not support an approval application. Did the trial meet statistical significance, or was the result borderline? Did the company stop the trial early for efficacy or safety? Early stopping for efficacy is positive; early stopping for safety is negative. What was the magnitude of benefit? A drug that reduces symptoms modestly meets an endpoint differently than one that reduces them substantially. What adverse events emerged? Rare, mild side effects are different from common, serious ones.

When a company announces a trial failure, the announcement usually specifies which endpoint was not met. A Phase 2 failure means the drug did not work as hoped, development typically stops. A Phase 3 failure is more costly; it means the drug worked in Phase 2 but did not work well enough, or worked no better than existing treatment, in a larger population. Phase 3 failures sometimes lead to additional trials, dose adjustments, or focus on subpopulations, but they often end development.

Understanding phase data allows you to distinguish between a setback (a Phase 2 failure that ends one drug but leaves the pipeline intact) and a major loss (a Phase 3 failure after years of investment). It also helps you assess whether a company's pipeline is advancing or stalling, a company with multiple drugs in Phase 3 is further along than one with drugs stuck in Phase 2, but also faces higher near-term risk of failure.

Do this automatically

Coordinating safety assessments across Phase 1's small cohorts, then scaling to Phase 2's hundreds of participants, then Phase 3's thousands of patients at multiple sites, and finally Phase 4's post-approval monitoring requires manual tracking of enrollment timelines, dosage records, adverse event reports, and regulatory submissions at each stage. Software platforms can automate the collection, organization, and reporting of these trial phase data to reduce administrative overhead. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.